 BOSTON, Sept. 30, 2021 GLOBE NEWSWIRE -- Aileron Therapeutics Nasdaq: ALRN, a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today announced it will present new preclinical data at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics demonstrating a potential secondary application of its novel, selective chemoprotective agent ALRN-6924 to also protect against radiation-induced toxicities. 